Expanded drug coverage

Effective this month Saskatchewan residents now have access to another treatment for multiple sclerosis (MS), Ocrevus.

Ocrevus is the first MS medication approved to treat early primary progressive MS, and the thirteenth option for patients with relapsing remitting MS, the most common form of the condition.

article continues below

“Our government is committed to providing Saskatchewan residents with better access to innovative new treatment options,” Health Minister Jim Reiter said. “Ocrevus will be the first drug treatment option approved for the primary progressive form of multiple sclerosis. It offers a treatment option that may slow the progression of multiple sclerosis and improve patients’ quality of life.”

The Saskatchewan Formulary offers a variety of options for MS treatment. Ocrevus is the first that can be used to treat both primary progressive MS and relapsing remitting MS. Last year, the provincial government spent about $17 million on MS medications for eligible patients.

Multiple Sclerosis is an autoimmune disease that attacks the central nervous system and leads to a progressive loss of motor skills. An estimated 3,700 people in Saskatchewan live with MS.

For more information on the approval process and income-assisted programs, contact the Drug Plan and Extended Benefits Branch at 1-800-667-7581 or 306-787-3317 in Regina.

© Copyright Yorkton This Week


NOTE: To post a comment you must have an account with at least one of the following services: Disqus, Facebook, Twitter, Google+ You may then login using your account credentials for that service. If you do not already have an account you may register a new profile with Disqus by first clicking the "Post as" button and then the link: "Don't have one? Register a new profile".

The Yorkton This Week welcomes your opinions and comments. We do not allow personal attacks, offensive language or unsubstantiated allegations. We reserve the right to edit comments for length, style, legality and taste and reproduce them in print, electronic or otherwise. For further information, please contact the editor or publisher, or see our Terms and Conditions.

comments powered by Disqus